Stroke

The researchers noted that future studies should examine the cost-effectiveness of CT compared with MRI as the best initial imaging modality for mechanical thrombectomy.

Neurology News Network for the week ending August 29, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Neurological deterioration was observed in about 1 of 7 patients who received in-hospital care for acute ischemic stroke or transient ischemic attack.

Endovascular treatment may benefit patients with emergent large vessel occlusion and target mismatch profiles regardless of the time from onset.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the end points and long-term goals of the phase 2 JUNIPER upper limb spasticity trial.

Future studies are needed to determine the preferential antihypertensive medication in patients after experiencing a stroke, despite the results suggesting a gap in secondary prevention of stroke.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

Results from the ATLAS Posterior PMA trial demonstrated that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the lack awareness and options for those who suffer from upper limb spasticity following a stroke.

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research discussed the recent phase 2 JUNIPER upper limb spasticity trial of daxibotulinumtoxinA for injection.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.

Neurology News Network for the week ending July 25, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

The study authors noted that clinicians should consider the data when recommending endovascular treatment for older adults.

In part 2 of this interview, the vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discusses future trials with ticagrelor and when they anticipate a possible FDA approval.

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discussed the findings of the THALES trial, and how ticagrelor stands alone among stroke treatments.

While further study is required, the data support vigilance of the symptoms and signs of acute ischemic stroke in patients with COVID-19 to reduce the burden of long-term disability.

Neurology News Network for the week ending July 18, 2020.

Neurology News Network for the week ending July 18, 2020.